{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:50Z","timestamp":1793325770366,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009123","name":"Norges Teknisk-Naturvitenskapelige Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing macrolide resistance makes treatment of <jats:italic>Mycoplasma genitalium<\/jats:italic> infections challenging. The second-line treatment is moxifloxacin, an antibiotic drug best avoided due to the potential of severe side effects and interactions. This study evaluates the effects of treatment with doxycycline 100\u00a0mg twice daily for 2 weeks as an alternative to moxifloxacin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective observational study examined the medical records of patients testing positive for macrolide resistant <jats:italic>Mycoplasma genitalium<\/jats:italic> from January 1st, 2016 to September 1st, 2019 in Trondheim, Norway. Information regarding symptoms as well as clinical and microbiological cure was collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>263 infections from 259 patients (161 females\/98 males) were examined. 155 (58.9%) had a negative test of cure following treatment. 34.7% of symptomatic patients not achieving microbiological cure experienced symptom relief or clearance. There was no statistical difference between bacterial loads in symptomatic versus asymptomatic patients. The mean difference was 1.6\u2009\u00d7\u200910<jats:sup>5<\/jats:sup> copies\/ml (95% CI \u2212\u00a01.4\u2009\u00d7\u200910<jats:sup>5<\/jats:sup>\u20134.8\u2009\u00d7\u200910<jats:sup>5<\/jats:sup>, p\u2009=\u20090.30) for women and 1.4\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> copies\/ml (95% CI -4.0\u2009\u00d7\u200910<jats:sup>5<\/jats:sup>\u20133.2\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>, p\u2009=\u20090.12) for men.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The cure rate of doxycycline in this study is higher than previously reported. This adds support to doxycycline\u2019s role in treatment before initiating treatment with less favorable drugs such as moxifloxacin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06910-1","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:02:42Z","timestamp":1638871362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of treatment with two weeks of doxycycline on macrolide-resistant strains of Mycoplasma genitalium: a retrospective observational study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5536-4248","authenticated-orcid":false,"given":"M.","family":"Goss\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Nordb\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pukstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"6910_CR1","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.000830","author":"R Gnanadurai","year":"2019","unstructured":"Gnanadurai R, Fifer H. Mycoplasma genitalium: a review. Microbiology. 2019. https:\/\/doi.org\/10.1099\/mic.0.000830.","journal-title":"Microbiology"},{"issue":"suppl_2","key":"6910_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/infdis\/jix198","volume":"216","author":"HC Wiesenfeld","year":"2017","unstructured":"Wiesenfeld HC, Manhart LE. Mycoplasma genitalium in women: current knowledge and research priorities for this recently emerged pathogen. J Infect Dis. 2017;216(suppl_2):389\u201395.","journal-title":"J Infect Dis"},{"issue":"3","key":"6910_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/cid\/civ312","volume":"61","author":"R Lis","year":"2015","unstructured":"Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61(3):418\u201326.","journal-title":"Clin Infect Dis"},{"key":"6910_CR4","unstructured":"2016 European guideline on Mycoplasma genitalium infections. https:\/\/iusti.org\/wp-content\/uploads\/2019\/12\/Jensen_et_al-2016-Journal_of_the_European_Academy_of_Dermatology_and_Venereology.pdf."},{"issue":"12","key":"6910_CR5","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1086\/593188","volume":"47","author":"JS Jensen","year":"2008","unstructured":"Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect. 2008;47(12):1546\u201353.","journal-title":"Clin Infect"},{"issue":"1","key":"6910_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/sextrans-2016-053060","volume":"94","author":"P Horner","year":"2018","unstructured":"Horner P, Ingle SM, Garrett F, Blee K, Kong F, Muir P, Moi H. Which azithromycin regimen should be used for treating Mycoplasma genitalium? A meta-analysis. Sex Transm Infect. 2018;94(1):14\u201320.","journal-title":"Sex Transm Infect"},{"issue":"9","key":"6910_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/cid\/civ644","volume":"61","author":"A Lau","year":"2015","unstructured":"Lau A, Bradshaw CS, Lewis D, Fairley CK, Chen MY, Kong FY, Hocking JS. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1389\u201399.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6910_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3201\/eid2305.161745","volume":"23","author":"GL Murray","year":"2017","unstructured":"Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM, Jensen JS, Fairley CK, Tabrizi SN. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis. 2017;23(5):809\u201312.","journal-title":"Emerg Infect Dis"},{"key":"6910_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025320","author":"DC Hooper","year":"2016","unstructured":"Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016. https:\/\/doi.org\/10.1101\/cshperspect.a025320.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6910_CR10","unstructured":"Moxifloxacin (systemic): Drug information. https:\/\/www.uptodate.com\/contents\/moxifloxacin-systemic-drug-information?search=moxifloxacin&source=search_result&selectedTitle=1~93&usage_type=default&display_rank=1#F9347994."},{"issue":"7","key":"6910_CR11","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1128\/JCM.00495-13","volume":"51","author":"KA Tagg","year":"2013","unstructured":"Tagg KA, Jeoffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. J Clin Microbiol. 2013;51(7):2245\u20139.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"6910_CR12","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1093\/jac\/dku164","volume":"69","author":"M Kikuchi","year":"2014","unstructured":"Kikuchi M, Ito S, Yasuda M, Tsuchiya T, Hatazaki K, Takanashi M, Ezaki T, Deguchi T. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother. 2014;69(9):2376\u201382.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"6910_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/0956462419890737","volume":"31","author":"M Fernandez-Huerta","year":"2020","unstructured":"Fernandez-Huerta M, Barbera MJ, Serra-Pladevall J, Esperalba J, Martinez-Gomez X, Centeno C, Pich OQ, Pumarola T, Espasa M. Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review. Int J STD AIDS. 2020;31(3):190\u20137.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"6910_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cmi.2017.09.006","volume":"24","author":"M Unemo","year":"2018","unstructured":"Unemo M, Salado-Rasmussen K, Hansen M, Olsen AO, Falk M, Golparian D, Aasterod M, Ringlander J, Nilsson CS, Sundqvist M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect. 2018;24(5):533\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"6910_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/0956462416688562","volume":"28","author":"Y Li","year":"2017","unstructured":"Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int J STD AIDS. 2017;28(11):1106\u201314.","journal-title":"Int J STD AIDS"},{"issue":"3","key":"6910_CR16","first-page":"553","volume":"73","author":"H Peyriere","year":"2018","unstructured":"Peyriere H, Makinson A, Marchandin H, Reynes J. Doxycycline in the management of sexually transmitted infections. J Antimicrob Chemother. 2018;73(3):553\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"6910_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1086\/599033","volume":"48","author":"LA Mena","year":"2009","unstructured":"Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect. 2009;48(12):1649\u201354.","journal-title":"Clin Infect"},{"issue":"7","key":"6910_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/cid\/cis1022","volume":"56","author":"LE Manhart","year":"2013","unstructured":"Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR, Hakhu NR, Thomas KK, Hughes JP, Jensen NL, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect. 2013;56(7):934\u201342.","journal-title":"Clin Infect"},{"issue":"2","key":"6910_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/ciq074","volume":"52","author":"JR Schwebke","year":"2011","unstructured":"Schwebke JR, Rompalo A, Taylor S, Sena AC, Martin DH, Lopez LM, Lensing S, Lee JY. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens\u2014a randomized clinical trial. Clin Infect Dis. 2011;52(2):163\u201370.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6910_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061481","volume":"8","author":"C Anagrius","year":"2013","unstructured":"Anagrius C, Lore B, Jensen JS. Treatment of Mycoplasma genitalium. Observations from a Swedish STD clinic. PLoS ONE. 2013;8(4): e61481.","journal-title":"PLoS ONE"},{"issue":"4","key":"6910_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/ciy477","volume":"68","author":"TRH Read","year":"2019","unstructured":"Read TRH, Fairley CK, Murray GL, Jensen JS, Danielewski J, Worthington K, Doyle M, Mokany E, Tan L, Chow EPF, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis. 2019;68(4):554\u201360.","journal-title":"Clin Infect Dis"},{"key":"6910_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1031","author":"D Durukan","year":"2019","unstructured":"Durukan D, Read TRH, Murray G, Doyle M, Chow EPF, Vodstrcil LA, Fairley CK, Aguirre I, Mokany E, Tan LY, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz1031.","journal-title":"Clin Infect Dis"},{"key":"6910_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/0956462419825948","author":"S Soni","year":"2019","unstructured":"Soni S, Horner P, Rayment M, Pinto-Sander N, Naous N, Parkhouse A, Bancroft D, Patterson C, Fifer H. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018). Int J STD AIDS. 2019. https:\/\/doi.org\/10.1177\/0956462419825948.","journal-title":"Int J STD AIDS"},{"key":"6910_CR24","unstructured":"Australian STI management guidelines for use in primary care: Mycoplasma genitalium. http:\/\/www.sti.guidelines.org.au\/sexually-transmissible-infections\/mycoplasma-genitalium#management."},{"issue":"10","key":"6910_CR25","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1128\/JCM.01233-16","volume":"54","author":"M Gosse","year":"2016","unstructured":"Gosse M, Lysvand H, Pukstad B, Nordbo SA. A novel simpleprobe PCR assay for detection of mutations in the 23S rRNA gene associated with macrolide resistance in Mycoplasma genitalium in clinical samples. J Clin Microbiol. 2016;54(10):2563\u20137.","journal-title":"J Clin Microbiol"},{"key":"6910_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.scitotenv.2014.08.075","volume":"500\u2013501","author":"X Van Doorslaer","year":"2014","unstructured":"Van Doorslaer X, Dewulf J, Van Langenhove H, Demeestere K. Fluoroquinolone antibiotics: an emerging class of environmental micropollutants. Sci Total Environ. 2014;500\u2013501:250\u201369.","journal-title":"Sci Total Environ"},{"issue":"2","key":"6910_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3201\/eid2402.170902","volume":"24","author":"TRH Read","year":"2018","unstructured":"Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, Murray GL, Chow EPF, Worthington K, Garland SM, et al. Use of Pristinamycin for macrolide-resistant Mycoplasma genitalium infection. Emerg Infect Dis. 2018;24(2):328\u201335.","journal-title":"Emerg Infect Dis"},{"key":"6910_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12879-015-0781-7","volume":"15","author":"A Guschin","year":"2015","unstructured":"Guschin A, Ryzhikh P, Rumyantseva T, Gomberg M, Unemo M. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect Dis. 2015;15:40.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"6910_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/andr.12078","volume":"3","author":"C Huang","year":"2015","unstructured":"Huang C, Zhu HL, Xu KR, Wang SY, Fan LQ, Zhu WB. Mycoplasma and ureaplasma infection and male infertility: a systematic review and meta-analysis. Andrology. 2015;3(5):809\u201316.","journal-title":"Andrology"},{"issue":"5","key":"6910_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.15537\/smj.2017.5.18820","volume":"38","author":"DA Alfarraj","year":"2017","unstructured":"Alfarraj DA, Somily AM. Isolation of Mycoplasma genitalium from endocervical swabs of infertile women. Saudi Med J. 2017;38(5):549\u201352.","journal-title":"Saudi Med J"},{"issue":"1","key":"6910_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/sti.2007.027375","volume":"84","author":"E Bjornelius","year":"2008","unstructured":"Bjornelius E, Anagrius C, Bojs G, Carlberg H, Johannisson G, Johansson E, Moi H, Jensen JS, Lidbrink P. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect. 2008;84(1):72\u20136.","journal-title":"Sex Transm Infect"},{"issue":"5","key":"6910_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/OLQ.0b013e31828bfccf","volume":"40","author":"J Vandepitte","year":"2013","unstructured":"Vandepitte J, Weiss HA, Kyakuwa N, Nakubulwa S, Muller E, Buve A, Van der Stuyft P, Hayes R, Grosskurth H. Natural history of Mycoplasma genitalium infection in a cohort of female sex workers in Kampala, Uganda. Sex Transm Dis. 2013;40(5):422\u20137.","journal-title":"Sex Transm Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06910-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:06:11Z","timestamp":1638871571000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06910-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6910"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06910-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethics Committee (REK midt 2018\/928) June 2018. An extended approval to include patients under the age of eighteen at the Youth Health Care Center was sought. Approval was granted in November 2019 and allowed the inclusion of patients sixteen years or above.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1225"}}